Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Encorafenib en binimetinib bij niet-resectabel of gemetastaseerd BRAF-gemuteerd melanoom
apr 2019 | Dermato-oncologie